Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Cellular Physiology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 15174093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function.

  2003cited by this paper
• Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases.

  2002cited by this paper
• 85-kDa Cytosolic Phospholipase A2 Mediates Peroxisome Proliferator-activated Receptor γ Activation in Human Lung Epithelial Cells*

  2002cited by this paper
• Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction.

  2002cited by this paper
• Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes.

  2002cited by this paper
• The mechanisms of action of PPARs.

  2002cited by this paper
• Nitration of PPARγ inhibits ligand‐dependent translocation into the nucleus in a macrophage‐like cell line, RAW 264

  2002cited by this paper
• Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes.

  2001cited by this paper
• New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

  2001cited by this paper
• Oxidative Stress in Cystic Fibrosis: Dietary and Metabolic Factors

  2001cited by this paper
• Glucose intolerance in cystic fibrosis patients.

  2001cited by this paper
• 15-Lipoxygenase-1 Metabolites Down-regulate Peroxisome Proliferator-activated Receptor γ via the MAPK Signaling Pathway*

  2001cited by this paper
• Metabolism of highly unsaturated n-3 and n-6 fatty acids.

  2000cited by this paper
• The Xenobiotic Compound 1,4-Bis[2-(3,5-Dichloropyridyloxy)]Benzene Is an Agonist Ligand for the Nuclear Receptor CAR

  2000cited by this paper
• Ligand type-specific Interactions of Peroxisome Proliferator-activated Receptor γ with Transcriptional Coactivators*

  2000cited by this paper
• The Nuclear Receptor PPARγ and Immunoregulation: PPARγ Mediates Inhibition of Helper T Cell Responses1

  2000cited by this paper
• A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.

  1999cited by this paper
• Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

  1999cited by this paper
• Troglitazone induces expression of PPARgamma in liver.

  1999cited by this paper
• A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice.

  1999cited by this paper
• A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.

  1999cited by this paper
• Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.

  1998cited by this paper
• Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.

  1998cited by this paper
• Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene.

  1998cited by this paper
• PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

  1998cited by this paper
• Terminal differentiation of human breast cancer through PPAR gamma.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.

  1998cited by this paper
• Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators.

  1997cited by this paper
• Insulin resistance is associated with decreased clinical status in cystic fibrosis.

  1997cited by this paper
• The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

  1997cited by this paper
• Essential fatty acid deficiency in well nourished young cystic fibrosis patients

  1997cited by this paper
• Peroxisome proliferator-activated receptor gamma1 expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytes.

  1997cited by this paper
• Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

  1997cited by this paper
• Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport.

  1997cited by this paper
• PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

  1997cited by this paper
• Bile duct epithelium: frontiers in transport physiology.

  1996cited by this paper
• Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.

  1996cited by this paper
• A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs.

  1996cited by this paper
• The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

  1996cited by this paper
• OB protein binds specifically to the choroid plexus of mice and rats.

  1996cited by this paper
• Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma.

  1996cited by this paper
• Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*)

  1995cited by this paper
• mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.

  1994cited by this paper
• Evidence for Increased oxidative Damage in Patients with Cystic Fibrosis

  1994cited by this paper
• Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.

  1994cited by this paper
• Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.

  1993cited by this paper
• Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors.

  1992cited by this paper
• Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

  1990cited by this paper
• Diabetes mellitus associated with cystic fibrosis.

  1988cited by this paper
• Fatty Acid Abnormalities in Cystic Fibrosis

  1985cited by this paper
• Endocrine pancreas in cystic fibrosis: an immunohistochemical study.

  1984cited by this paper

• A New Frontier in Cystic Fibrosis Pathophysiology: How and When Clock Genes Can Affect the Inflammatory/Immune Response in a Genetic Disease Model

  2024cites this paper
• Novel Immunomodulatory Therapies for Respiratory Pathologies

  2022cites this paper
• Transcriptome analysis of the distal small intestine of Cftr null mice.

  2020cites this paper
• Resveratrol restores intracellular transport in cystic fibrosis epithelial cells.

  2020cites this paper
• The role of essential fatty acids in cystic fibrosis and normalizing effect of fenretinide

  2020cites this paper
• Bromide alleviates fatty acid‐induced lipid accumulation in mouse primary hepatocytes through the activation of PPARα signals

  2019cites this paper
• Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice

  2019cites this paper
• Small adipose stores in cystic fibrosis mice are characterized by reduced cell volume, not cell number.

  2018cites this paper
• The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy

  2017cites this paper
• Powerful tools for genetic modification: Advances in gene editing

  2017cites this paper
• Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside

  2017cites this paper
• Ineffective correction of PPARγ signaling in cystic fibrosis airway epithelial cells undergoing repair.

  2016cites this paper
• Innate and Adaptive Immunity in Cystic Fibrosis.

  2016cites this paper
• Cystic Fibrosis Lung Immunity: The Role of the Macrophage

  2016cites this paper
• High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine

  2016cites this paper
• Role of PPARα in the attenuation of bile acid-induced apoptosis by omega-3 long-chain polyunsaturated fatty acids in cultured hepatocytes

  2016cites this paper
• Early pulmonary inflammation and lung damage in children with cystic fibrosis

  2015cites this paper
• Microtubule Regulation in Cystic Fibrosis Pathophysiology

  2015cites this paper
• Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.

  2015cites this paper
• Symposium Summaries

  2015cites this paper
• Cystic fibrosis: evidence for gut inflammation.

  2014cites this paper
• Antibiotic and anti-inflammatory therapies for cystic fibrosis.

  2013cites this paper
• Reduced Caveolin-1 Promotes Hyperinflammation due to Abnormal Heme Oxygenase-1 Localization in Lipopolysaccharide-Challenged Macrophages with Dysfunctional Cystic Fibrosis Transmembrane Conductance Regulator

  2013cites this paper
• A diet containing soybean oil heated for three hours increases adipose tissue weight but decreases body weight in C57BL/6 J mice

  2013cites this paper
• Virulence profiles of Shiga Toxin-Producing Escherichia coli and other potentially diarrheagenic E.coli of bovine origin, in Mendoza, Argentina

  2013cites this paper
• The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis – a pilot study

  2012cites this paper
• Systemic Analysis of PPARγ in Mouse Macrophage Populations Reveals Marked Diversity in Expression with Critical Roles in Resolution of Inflammation and Airway Immunity

  2012cites this paper
• ImmunityResolution of Inflammation and Airway Diversity in Expression with Critical Roles in Macrophage Populations Reveals Marked in Mouse g Systemic Analysis of PPAR

  2012cites this paper
• PPARγ as a therapeutic target in cystic fibrosis.

  2012cites this paper
• Association of serum uric acid with Pro12Ala polymorphism in PPAR-γ2 among Chinese nonagenarians/centenarians

  2012cites this paper
• Mouse models of cystic fibrosis: phenotypic analysis and research applications.

  2011cites this paper
• Pharmacological correction of a defect in PPARγ signaling ameliorates disease severity in Cftr-deficient mice

  2010cites this paper
• High-Dose Ibuprofen in Cystic Fibrosis

  2010cites this paper
• Potential of anti-inflammatory treatment for cystic fibrosis lung disease

  2010cites this paper
• Lipids control mucus production in cystic fibrosis

  2010cites this paper
• Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors

  2010cites this paper
• Protein biomarkers in cystic fibrosis research: where next?

  2010cites this paper
• The Role of Inhaled Corticosteroids in the Management of Cystic Fibrosis

  2009cites this paper
• Immunological mechanisms controlling chronic inflammatory diseases

  2009cites this paper
• Hyperinflammation in airways of cystic fibrosis patients: what’s new?

  2008cites this paper
• Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice.

  2008cites this paper
• Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases

  2008cites this paper
• Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling

  2008cites this paper
• Expression of cystic fibrosis transmembrane conductance regulator in the human distal lung.

  2008cites this paper
• Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease

  2008cites this paper
• Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium.

  2008cites this paper
• Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages.

  2008cites this paper
• Sputum biomarkers of inflammation in cystic fibrosis lung disease.

  2007cites this paper
• Inflammation and anti-inflammatory therapies for cystic fibrosis.

  2007cites this paper
• Peroxisome proliferator-activated receptor gamma interacts with CIITA x RFX5 complex to repress type I collagen gene expression.

  2007cites this paper
• Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis.

  2007cites this paper
• Decreased Peroxisome Proliferator Activated Receptor &agr; Is Associated with Bile Duct Injury in Cystic Fibrosis Transmembrane Conductance Regulator−/− Mice

  2006cites this paper
• Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes

  2006cites this paper
• Diabetes: a major co-morbidity of cystic fibrosis.

  2005cites this paper
• The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases

  2005cites this paper